Effectiveness of topiramate in lipomatosis comorbid with agoraphobia and migraine. Case study
More details
Hide details
Dept of Psychiatry, HELIOS Klinikum Aue
Submission date: 2014-08-13
Final revision date: 2014-11-26
Acceptance date: 2014-11-28
Publication date: 2015-03-23
Corresponding author
Josef Koch   

Dept of Psychiatry, HELIOS Klinikum Aue, Gartenstraße 6, 08280 Aue, Germany
Arch Psych Psych 2015;17(1):5-8
Topiramate has been used in epilepsy and migraine for more than ten years. Recently, it has gained importance in the treatment of obesity, particularly in combination with phentermine. We report the case of a 51-year-old woman suffering from agoraphobia with panic attacks, diabetes and migraine. In addition, she simultaneously developed generalized lipomatosis leading to a weight gain of more than 20[th]kg. She was given topiramate up to 100[th]mg per day in addition to an SSRI (citalopram) and a melatoninergic drug (agomelatine). Gradually, within two years after starting topiramate, she lost 20[th]kg, with a corresponding reduction of thorax and arm circumference. Although the mechanism of weight loss remains to be clarified, topiramate may be an alternative approach in patients suffering from generalized lipomatosis.
Journals System - logo
Scroll to top